| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 256.5 | 27.6 |
| Profit before tax | 173.2 | -18.3 |
| Net income | 173.7 | -19.6 |
| EPS (diluted, $ a share) | $2.28 | $-0.26 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +828.7% |
|---|---|
| Operating margin | 69.2% |
10-Q filed with the SEC, NASDAQ: ZYME. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zymeworks Inc.: key numbers
- Share price
- $26.45Close, Nov 16
- Market cap
- $1.83B
- Shares outstanding
- 69.03MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zymeworks Inc.
All →Zymeworks CSO Paul Andrew Moore Sells $1.04M of Stock
Paul Andrew Moore, CSO, sold 39,741 shares of Zymeworks Inc. at $26.04 to $26.14 a share (average $26.07) in 3 transactions, worth $1.04M in total on Nov 13, 2026. Shares held after the trade: 33,756 (-42.5%).
- Value
- $1.04M
- Shares
- 39,741
- Average price
- $26.07
- Role
- CSO
- Holding change
- -42.5%
- Trade date
- Nov 13, 2026
Zymeworks Announces $200M Stock Buyback
Zymeworks authorized a new $200 million share repurchase program through 2028, following the completion of its initial $125 million program. The company expects to spend approximately $140 million under this new authorization to reduce share count and return capital to shareholders.
- Value
- $200M
- Term
- through 2028
Zymeworks M&A Deal with Theravance Biopharma, Inc.
Zymeworks Inc. filed an amendment to its previous 8-K to provide historical and pro forma financial statements following its completed acquisition of Theravance Biopharma, Inc. The merger involved a cash payment of $17.00 per share plus a contingent value right (CVR) tied to the future monetization and commercial success of ampreloxetine. The cash portion of the deal was financed through $350 million in non-recourse notes from OMERS Life Sciences and existing cash reserves.
- Counterparty
- Theravance Biopharma, Inc.
Zymeworks Financial Results
Zymeworks reported Q3 2026 financial results and significantly raised its full-year 2026 revenue guidance to $337M-$351M. The company highlighted the recent FDA approval of Ziihera for first-line GEA, which triggered a $250 million milestone payment from Jazz Pharmaceuticals, and the completion of its acquisition of Theravance Biopharma.
- Term
- Q3 2026
“We are entering the next phase of Zymeworks growth with a fundamentally stronger and more diversified business. The transformation of Zymeworks is becoming increasingly visible in our financial profile and in the breadth of opportunities available to us.”
Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks
“These advancements demonstrate the strategy we set out a year ago - to build a durable financial foundation through partnered and commercial assets, while maintaining the ability to create additional value through R&D, acquisitions, partnerships and disciplined capital allocation.”
Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks
Zymeworks Licensing Deal with Roche Worth $813M
Zymeworks entered into a global collaboration and license agreement with Roche for the development and commercialization of ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks will receive a $55 million upfront payment and a $40 million milestone upon Phase 1b trial initiation, with eligibility for up to $718 million in additional milestones plus tiered royalties.
- Value
- $813M
- Counterparty
- Roche
Zymeworks EVP, Head of R&D Adam Schayowitz Sells $358K of Stock
Adam Schayowitz, EVP, Head of R&D, sold 13,832 shares of Zymeworks Inc. at $25.85 a share, worth $358K in total on Oct 9, 2026. Shares held after the trade: 23,205 (-37.3%).
- Value
- $358K
- Shares
- 13,832
- Price
- $25.85
- Role
- EVP, Head of R&D
- Holding change
- -37.3%
- Trade date
- Oct 9, 2026